Disease Clusters?

Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.

← Back to all clusters

Cluster 13

24 diseases · 35 shared-gene connections
24 Diseases
520 Unique genes
0.084 Avg. similarity score
Hypotension Most-connected disease (7 links)
Log in to save this analysis

Save This Analysis

Disease Searched: Dyskinesia, drug-induced Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵ Connections in cluster ⇵ Significant partners ⇵ Curated genes ⇵
Hypotension 7 7 67
Bradycardia 6 6 26
Amphetamine or sympathomimetic abuse 5 5 77
Dyskinesia, drug-induced 5 5 15
Hyperkinesia 5 5 33
Movement disorder 5 5 57
Tremor 5 5 15
Catalepsy 4 4 16
Seizures 4 4 141
Amnesia 3 3 18
Substance-induced psychosis 3 3 17
Bradyopsia 2 2 2
Cyp2d6 deficiency 2 2 1
Edema 2 2 49
Essential tremor 2 2 97
Hyperalgesia 2 2 89
Catatonia 1 1 1
Neurogenic bladder 1 1 1
Periodic limb movement disorder 1 1 11
Retrograde amnesia 1 1 1
immunodeficiency 92 1 1 1
neurodevelopmental disorder with cerebellar atrophy and motor dysfunction 1 1 1
neurodevelopmental disorder with language impairment and behavioral abnormalities 1 1 1
seizures, early-onset, with neurodegeneration and brain calcifications 1 1 1

Top shared genes (genes linked to 2+ member diseases ‐ top 100 shown, download for all)

Gene ⇵ Member diseases ⇵ Linked diseases
DRD2 8 / 24 Amphetamine or sympathomimetic abuse, Bradycardia, Catalepsy, Dyskinesia, drug-induced and 4 more
DRD3 8 / 24 Amphetamine or sympathomimetic abuse, Dyskinesia, drug-induced, Essential tremor, Hyperalgesia and 4 more
PDYN 8 / 24 Amnesia, Amphetamine or sympathomimetic abuse, Bradycardia, Dyskinesia, drug-induced and 4 more
ADORA2A 7 / 24 Amphetamine or sympathomimetic abuse, Hyperkinesia, Hypotension, Movement disorder and 3 more
DRD1 7 / 24 Amphetamine or sympathomimetic abuse, Catalepsy, Dyskinesia, drug-induced, Hyperkinesia and 3 more
POMC 6 / 24 Amnesia, Bradycardia, Catalepsy, Edema and 2 more
AGT 5 / 24 Bradycardia, Catalepsy, Hyperalgesia, Hypotension and 1 more
CNR1 5 / 24 Catalepsy, Hyperalgesia, Hypotension, Movement disorder and 1 more
IL6 5 / 24 Amnesia, Edema, Hyperalgesia, Hypotension and 1 more
OPRM1 5 / 24 Amphetamine or sympathomimetic abuse, Hyperalgesia, Movement disorder, Seizures and 1 more
TAC1 5 / 24 Amnesia, Bradycardia, Edema, Hyperalgesia and 1 more
TRH 5 / 24 Amnesia, Bradycardia, Catalepsy, Seizures and 1 more
ACHE 4 / 24 Amphetamine or sympathomimetic abuse, Movement disorder, Seizures, Tremor
CALCA 4 / 24 Catalepsy, Edema, Hyperalgesia, Hyperkinesia
CAT 4 / 24 Dyskinesia, drug-induced, Edema, Hypotension, Seizures
CCK 4 / 24 Catalepsy, Dyskinesia, drug-induced, Hyperkinesia, Seizures
CRH 4 / 24 Bradycardia, Hypotension, Movement disorder, Seizures
CYP2D6 4 / 24 Amphetamine or sympathomimetic abuse, Bradycardia, Cyp2d6 deficiency, Tremor
FOS 4 / 24 Amphetamine or sympathomimetic abuse, Hyperalgesia, Hyperkinesia, Seizures
GCG 4 / 24 Bradycardia, Catalepsy, Hyperkinesia, Hypotension
GSTP1 4 / 24 Amphetamine or sympathomimetic abuse, Essential tremor, Movement disorder, Substance-induced psychosis
HTR1A 4 / 24 Bradycardia, Seizures, Substance-induced psychosis, Tremor
KNG1 4 / 24 Bradycardia, Edema, Hyperalgesia, Hypotension
NGF 4 / 24 Amnesia, Hyperalgesia, Hyperkinesia, Seizures
OXT 4 / 24 Edema, Hyperkinesia, Hypotension, Seizures
ADORA1 3 / 24 Bradycardia, Catalepsy, Hypotension
AVP 3 / 24 Amnesia, Hyperalgesia, Hypotension
CNTNAP5 3 / 24 Essential tremor, Movement disorder, Periodic limb movement disorder
EDN1 3 / 24 Bradycardia, Hyperalgesia, Hypotension
GDNF 3 / 24 Amphetamine or sympathomimetic abuse, Dyskinesia, drug-induced, Hyperalgesia
HCN1 3 / 24 Movement disorder, Periodic limb movement disorder, Seizures
HTR1B 3 / 24 Amphetamine or sympathomimetic abuse, Hypotension, Seizures
IGF1 3 / 24 Essential tremor, Hyperalgesia, Movement disorder
IL1A 3 / 24 Amnesia, Hyperalgesia, Hypotension
IL1B 3 / 24 Hyperalgesia, Hypotension, Seizures
IL2 3 / 24 Amnesia, Hyperkinesia, Hypotension
INS 3 / 24 Edema, Hypotension, Seizures
MAP2K5 3 / 24 Amphetamine or sympathomimetic abuse, Movement disorder, Periodic limb movement disorder
NOS1 3 / 24 Amphetamine or sympathomimetic abuse, Hyperalgesia, Seizures
NTS 3 / 24 Bradycardia, Catalepsy, Hyperkinesia
PRL 3 / 24 Bradycardia, Catalepsy, Hypotension
PTGS2 3 / 24 Edema, Hyperalgesia, Seizures
RGS9 3 / 24 Bradyopsia, Dyskinesia, drug-induced, Substance-induced psychosis
SLC12A5 3 / 24 Hyperalgesia, Movement disorder, Seizures
SLC6A3 3 / 24 Amphetamine or sympathomimetic abuse, Hyperkinesia, Substance-induced psychosis
TH 3 / 24 Catalepsy, Dyskinesia, drug-induced, Hyperkinesia
TNF 3 / 24 Edema, Hyperalgesia, Hypotension
VIP 3 / 24 Edema, Hyperalgesia, Hypotension
ACE 2 / 24 Hypotension, Substance-induced psychosis
ADRA1B 2 / 24 Hypotension, Seizures
AKT1 2 / 24 Amphetamine or sympathomimetic abuse, Substance-induced psychosis
APOE 2 / 24 Amnesia, Seizures
ATP7A 2 / 24 Seizures, Tremor
BCHE 2 / 24 Hyperkinesia, Seizures
BDKRB2 2 / 24 Hyperalgesia, Hypotension
BDNF 2 / 24 Amphetamine or sympathomimetic abuse, Seizures
BTBD9 2 / 24 Movement disorder, Periodic limb movement disorder
CACNA1D 2 / 24 Bradycardia, Edema
CCDC148 2 / 24 Movement disorder, Periodic limb movement disorder
CHRM2 2 / 24 Bradycardia, Neurogenic bladder
CHRM4 2 / 24 Catatonia, Tremor
CNR2 2 / 24 Catalepsy, Hyperalgesia
COMT 2 / 24 Amphetamine or sympathomimetic abuse, Hyperalgesia
CRHR1 2 / 24 Hyperalgesia, Hyperkinesia
CTNNA3 2 / 24 Edema, Essential tremor
CXCL8 2 / 24 Edema, Hyperalgesia
DPP6 2 / 24 Essential tremor, Movement disorder
EDN2 2 / 24 Bradycardia, Hypotension
EDN3 2 / 24 Bradycardia, Hypotension
EMB 2 / 24 Movement disorder, Periodic limb movement disorder
FOSB 2 / 24 Dyskinesia, drug-induced, Movement disorder
GABBR1 2 / 24 Amphetamine or sympathomimetic abuse, Hyperkinesia
GABRA1 2 / 24 Essential tremor, Seizures
GABRG2 2 / 24 Amphetamine or sympathomimetic abuse, Seizures
GAD1 2 / 24 Amphetamine or sympathomimetic abuse, Dyskinesia, drug-induced
GAD2 2 / 24 Amphetamine or sympathomimetic abuse, Seizures
GEMIN5 2 / 24 Essential tremor, neurodevelopmental disorder with cerebellar atrophy and motor dysfunction
GNAI1 2 / 24 Amnesia, Essential tremor
GNAO1 2 / 24 Essential tremor, Movement disorder
GRIA1 2 / 24 Hyperkinesia, Hypotension
GRIA2 2 / 24 Hyperkinesia, neurodevelopmental disorder with language impairment and behavioral abnormalities
GRIN2B 2 / 24 Hyperalgesia, Hypotension
GRM2 2 / 24 Amphetamine or sympathomimetic abuse, Substance-induced psychosis
GSTM1 2 / 24 Amphetamine or sympathomimetic abuse, Movement disorder
HTR2A 2 / 24 Hyperalgesia, Hyperkinesia
HTR6 2 / 24 Amphetamine or sympathomimetic abuse, Substance-induced psychosis
LMO1 2 / 24 Movement disorder, Periodic limb movement disorder
MECP2 2 / 24 Hyperalgesia, Seizures
MEIS1 2 / 24 Movement disorder, Periodic limb movement disorder
MYT1 2 / 24 Movement disorder, Periodic limb movement disorder
NISCH 2 / 24 Bradycardia, Hypotension
NKAIN2 2 / 24 Essential tremor, Hypotension
NLRP1 2 / 24 Essential tremor, Hypotension
NOS2 2 / 24 Hyperalgesia, Seizures
NPY 2 / 24 Hyperkinesia, Seizures
NPY1R 2 / 24 Amphetamine or sympathomimetic abuse, Substance-induced psychosis
NRG1 2 / 24 Amphetamine or sympathomimetic abuse, Movement disorder
NRROS 2 / 24 Seizures, seizures, early-onset, with neurodegeneration and brain calcifications
PICK1 2 / 24 Amphetamine or sympathomimetic abuse, Substance-induced psychosis
PLAT 2 / 24 Amphetamine or sympathomimetic abuse, Hypotension
What do these columns mean?
Connections in cluster
How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners
How many of those links are statistically significant (FDR q < 0.05).
Curated genes
Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes)
How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y)
x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count
Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment
Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value
Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster)
Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster)
Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵ Source ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
Neuroactive ligand-receptor interaction
AVP, GRP, HRH3, PDYN, POMC, TAC1, TRH, ADORA2A, DRD1, DRD2, DRD3, DRD4
 KEGG 90 / 370 5.6× 1.72e-43 1.60e-39 ✓ sig.
cAMP signaling pathway
GNAI1, GNAI3, POMC, ADORA2A, AKT1, BDNF, DRD1, DRD2, FOS, GABBR1, HTR1B, HTR6
 KEGG 59 / 226 6.0× 2.76e-30 7.49e-27 ✓ sig.
Hormone signaling
AVP, GNAI1, GNAI3, PDYN, POMC, TRH, DRD1, DRD2, DRD3, DRD4, NOS1, OPRM1
 KEGG 55 / 219 5.8× 2.39e-27 4.92e-24 ✓ sig.
Peptide ligand-binding receptors
GRP, PDYN, POMC, TRH, NPY1R, OPRM1, PROKR2, AGT, EDN1, EDN2, EDN3, KNG1
 Reactome 36 / 106 7.8× 3.85e-23 4.92e-20 ✓ sig.
Cholinergic synapse
GNAI1, GNAI3, ACHE, AKT1, FOS, CACNA1D, CHRM2, GNAI2, FYN, CHRM4, GNAO1, PIK3R1
 KEGG 32 / 115 6.4× 9.04e-18 4.76e-15 ✓ sig.
G alpha (q) signalling events
APP, AVP, GRP, TAC1, TRH, PROKR2, RGS17, AGT, EDN1, EDN2, EDN3, GCG
 Reactome 37 / 172 5.0× 2.55e-16 1.04e-13 ✓ sig.
Serotonergic synapse
APP, GNAI1, GNAI3, CYP2D6, HTR1B, HTR3A, HTR6, SLC6A4, CACNA1D, GNAI2, HTR1A, CASP3
 KEGG 30 / 115 6.0× 6.90e-16 2.63e-13 ✓ sig.
Chagas disease
GNAI1, GNAI3, IL2, IL6, AKT1, FOS, RELA, GNAI2, KNG1, CASP8, CXCL8, TNF
 KEGG 28 / 103 6.3× 2.05e-15 7.16e-13 ✓ sig.
Circadian entrainment
GNAI1, GNAI3, FOS, NOS1, PRKG1, CACNA1D, GNAI2, GNAO1, CACNA1H, CAMK2A, GRIN1, GRIN2B
 KEGG 26 / 97 6.2× 3.03e-14 8.56e-12 ✓ sig.
Dopaminergic synapse
GNAI1, GNAI3, AKT1, ARRB2, COMT, DRD1, DRD2, DRD3, DRD4, FOS, SLC6A3, CACNA1D
 KEGG 30 / 132 5.2× 3.88e-14 1.07e-11 ✓ sig.
Cocaine addiction
GNAI1, GNAI3, PDYN, BDNF, DRD1, DRD2, GRM2, RELA, SLC6A3, GNAI2, RGS9, PPP1R1B
 KEGG 19 / 49 9.0× 5.04e-14 1.34e-11 ✓ sig.
Inflammatory mediator regulation of TRP channels
NGF, KNG1, MAP2K6, IGF1, PIK3R1, ALOX12, BDKRB1, BDKRB2, CAMK2A, HTR2A, IL1B, MAPK8
 KEGG 26 / 99 6.1× 5.16e-14 1.37e-11 ✓ sig.
G alpha (i) signalling events
APP, GNAI1, GNAI3, HRH3, PDYN, POMC, DRD3, DRD4, GABBR1, GRM2, HTR1B, NPY1R
 Reactome 40 / 249 3.7× 4.71e-13 1.07e-10 ✓ sig.
AGE-RAGE signaling pathway in diabetic complications
IL1A, IL6, AKT1, RELA, AGT, EDN1, CASP3, CXCL8, TNF, PIK3R1, AGER, CCL2
 KEGG 25 / 101 5.7× 6.88e-13 1.52e-10 ✓ sig.
Calcium signaling pathway
NGF, ADORA2A, DRD1, GDNF, HTR6, NOS1, CACNA1D, CHRM2, TACR1, BDKRB1, BDKRB2, CACNA1H
 KEGG 39 / 254 3.5× 4.02e-12 7.78e-10 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵ GO ID ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
chemical synaptic transmission
APP, HRH3, PDYN, TAC1, DRD4, GABRG2, GAD1, GAD2, GRM2, HTR1B, HTR3A, HTR6
 GO:0007268 57 / 236 8.7× 3.17e-37 2.74e-33 ✓ sig.
response to hypoxia
COMT, DRD2, NOS1, PLAT, SLC6A4, ADORA1, CYP1A1, EDN1, TH, CAT, PENK, CASP3
 GO:0001666 38 / 176 7.8× 3.24e-23 8.23e-20 ✓ sig.
response to ethanol
AVP, IL2, DRD2, DRD3, FOS, GABBR1, GSTP1, RELA, SLC6A3, CRH, GNRH1, TACR1
 GO:0045471 30 / 110 9.8× 1.00e-21 2.04e-18 ✓ sig.
sensory perception of pain
NGF, TAC1, ARRB2, NPY1R, OPRM1, PENK, AQP1, CHRNB2, CCL2, HOXD1, MAPK3, MC1R
 GO:0019233 21 / 44 17.2× 1.61e-21 3.16e-18 ✓ sig.
response to xenobiotic stimulus
AVP, ADORA2A, COMT, DRD1, DRD2, DRD3, FOS, RELA, SLC6A3, SLC6A4, SNCA, CRH
 GO:0009410 42 / 248 6.1× 3.09e-21 5.85e-18 ✓ sig.
signal transduction
AVP, CSF2, GNAI1, GNAI3, GRP, HRH3, NGF, POMC, TRH, ADORA2A, AKT1, ARRB2
 GO:0007165 135 / 2,125 2.3× 6.08e-21 1.10e-17 ✓ sig.
response to nicotine
AVP, DRD2, GABBR1, SLC6A3, EDN1, TACR1, FOSB, PENK, CASP3, CHRNB2, MAPK1, ABAT
 GO:0035094 19 / 40 17.1× 1.54e-19 2.23e-16 ✓ sig.
monoatomic ion transport
GABRG2, HTR3A, TRPM3, CACNA1D, KCNN2, SLC9A1, SLC9A2, SLC9A3, GABRA1, PKD1L3, SLC1A2, SLC24A2
 GO:0006811 66 / 667 3.6× 1.94e-19 2.78e-16 ✓ sig.
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
HRH3, DRD1, DRD4, HTR1B, HTR6, NPY1R, OPRM1, CHRM2, HTR1A, CNR1, CNR2, CHRM4
 GO:0007187 21 / 54 14.0× 3.21e-19 4.36e-16 ✓ sig.
excitatory postsynaptic potential
ADORA2A, AKT1, ARRB2, DRD2, HTR3A, SNCA, ADORA1, CHRNB2, GRIN1, GRIN2B, MECP2, P2RX2
 GO:0060079 23 / 69 12.0× 3.78e-19 5.03e-16 ✓ sig.
locomotory behavior
APP, AVP, ADORA2A, DRD1, DRD2, DRD3, NPY1R, SLC6A3, PPP1R1B, TH, PENK, GNAO1
 GO:0007626 26 / 99 9.4× 1.52e-18 1.89e-15 ✓ sig.
monoatomic ion transmembrane transport
GABRG2, HTR3A, TRPM3, CACNA1D, KCNN2, GABRA1, PKD1L3, SLC24A2, CHRNB2, KCNA6, CACNA1H, CACNA2D1
 GO:0034220 49 / 404 4.4× 3.22e-18 3.88e-15 ✓ sig.
neuropeptide signaling pathway
GNAI1, GRP, PDYN, POMC, TAC1, NPY1R, OPRM1, PROKR2, RELA, NTS, PENK, CARTPT
 GO:0007218 25 / 111 8.1× 3.71e-16 3.23e-13 ✓ sig.
regulation of blood pressure
POMC, TAC1, COMT, NPY1R, AGT, EDN1, TACR1, UTS2, CALCA, GCH1, PTGS2, PTGS1
 GO:0008217 22 / 83 9.5× 5.53e-16 4.66e-13 ✓ sig.
vasodilation
APOE, ADORA2A, DRD1, NOS1, PRKG1, ADORA1, KNG1, CALCA, INS, TNF, BDKRB2, GPER1
 GO:0042311 18 / 50 12.9× 5.93e-16 4.93e-13 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵ Disease B ⇵ Similarity score ⇵ Shared genes ⇵ P-value ⇵ FDR q-value ⇵
Movement disorder Periodic limb movement disorder 0.190 11 6.41e-28 1.81e-26 ✓ sig.
Bradycardia Hypotension 0.175 14 1.89e-27 5.23e-26 ✓ sig.
Hyperalgesia Hypotension 0.106 15 2.12e-20 4.10e-19 ✓ sig.
Amphetamine or sympathomimetic abuse Substance-induced psychosis 0.118 10 1.01e-19 1.90e-18 ✓ sig.
Bradycardia Catalepsy 0.229 8 2.55e-19 4.67e-18 ✓ sig.
Hypotension Seizures 0.077 15 2.88e-17 4.76e-16 ✓ sig.
Catalepsy Hypotension 0.105 8 1.04e-15 1.56e-14 ✓ sig.
Catalepsy Hyperkinesia 0.163 7 1.19e-15 1.77e-14 ✓ sig.
Movement disorder Seizures 0.070 13 3.15e-15 4.54e-14 ✓ sig.
Amphetamine or sympathomimetic abuse Movement disorder 0.089 11 3.57e-15 5.13e-14 ✓ sig.
Edema Hypotension 0.093 10 8.68e-15 1.22e-13 ✓ sig.
Amphetamine or sympathomimetic abuse Seizures 0.063 13 2.02e-13 2.58e-12 ✓ sig.
Amnesia Hypotension 0.089 7 6.55e-13 8.02e-12 ✓ sig.
Edema Hyperalgesia 0.069 9 8.09e-12 8.95e-11 ✓ sig.
Amphetamine or sympathomimetic abuse Dyskinesia, drug-induced 0.069 6 6.19e-11 6.29e-10 ✓ sig.
Hyperkinesia Hypotension 0.074 7 8.36e-11 8.40e-10 ✓ sig.
Dyskinesia, drug-induced Hyperkinesia 0.114 5 9.74e-11 9.68e-10 ✓ sig.
Amphetamine or sympathomimetic abuse Hyperkinesia 0.067 7 2.28e-10 2.20e-9 ✓ sig.
Catalepsy Dyskinesia, drug-induced 0.143 4 1.05e-9 9.53e-9 ✓ sig.
Dyskinesia, drug-induced Movement disorder 0.074 5 1.70e-9 1.51e-8 ✓ sig.
Amnesia Bradycardia 0.098 4 1.92e-8 1.51e-7 ✓ sig.
Essential tremor Movement disorder 0.040 6 1.50e-6 8.52e-6 ✓ sig.
Bradycardia Tremor 0.077 3 1.92e-6 1.07e-5 ✓ sig.
Substance-induced psychosis Tremor 0.065 2 1.19e-4 3.93e-4 ✓ sig.
Cyp2d6 deficiency Tremor 0.063 1 9.74e-4 1.67e-3 ✓ sig.
Catatonia Tremor 0.063 1 9.74e-4 1.67e-3 ✓ sig.
immunodeficiency 92 Tremor 0.063 1 9.74e-4 1.67e-3 ✓ sig.
Amnesia Retrograde amnesia 0.053 1 1.17e-3 1.90e-3 ✓ sig.
Bradycardia Cyp2d6 deficiency 0.037 1 1.69e-3 2.53e-3 ✓ sig.
Bradycardia Neurogenic bladder 0.037 1 1.69e-3 2.53e-3 ✓ sig.
Bradyopsia Dyskinesia, drug-induced 0.059 1 1.95e-3 2.83e-3 ✓ sig.
Hyperkinesia neurodevelopmental disorder with language impairment and behavioral abnormalities 0.029 1 2.14e-3 3.04e-3 ✓ sig.
Bradyopsia Substance-induced psychosis 0.053 1 2.21e-3 3.11e-3 ✓ sig.
Essential tremor neurodevelopmental disorder with cerebellar atrophy and motor dysfunction 0.010 1 6.30e-3 7.56e-3 ✓ sig.
Seizures seizures, early-onset, with neurodegeneration and brain calcifications 0.007 1 9.16e-3 1.05e-2 ✓ sig.